
    
      The investigators conduct this clinical trial to evaluate the treatment outcome of RFA in HCC
      patients with tumor smaller than 7cm and tumor number less than five ,in comparison with TACE
      treatment.The primary outcome is overall survival.The secondary outcome is objective response
      rate.
    
  